Bill Text: CA AB1288 | 2023-2024 | Regular Session | Amended
NOTE: There are more recent revisions of this legislation. Read Latest Draft
Bill Title: Health care coverage: Medication-assisted treatment.
Spectrum: Partisan Bill (Democrat 3-0)
Status: (Vetoed) 2024-01-25 - Consideration of Governor's veto stricken from file. [AB1288 Detail]
Download: California-2023-AB1288-Amended.html
a naloxone product, any of the following to prior authorization or step therapy: a naloxone product, any of the following to prior authorization or step therapy:
Bill Title: Health care coverage: Medication-assisted treatment.
Spectrum: Partisan Bill (Democrat 3-0)
Status: (Vetoed) 2024-01-25 - Consideration of Governor's veto stricken from file. [AB1288 Detail]
Download: California-2023-AB1288-Amended.html
Amended
IN
Senate
July 13, 2023 |
Amended
IN
Senate
July 05, 2023 |
CALIFORNIA LEGISLATURE—
2023–2024 REGULAR SESSION
Assembly Bill
No. 1288
Introduced by Assembly Member Rendon (Coauthors: Assembly Members Reyes and Schiavo) |
February 16, 2023 |
An act to add Section 1342.75 to the Health and Safety Code, and to add Section 10123.1934 to the Insurance Code, relating to health care coverage.
LEGISLATIVE COUNSEL'S DIGEST
AB 1288, as amended, Rendon.
Health care coverage: Medication-assisted treatment.
Existing law, the Knox–Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law authorizes health care service plans and health insurers that cover prescription drugs to utilize reasonable medical management practices, including prior authorization and step therapy, consistent with applicable law.
This bill would prohibit a medical service plan and a health insurer from subjecting a naloxone product, or another opioid antagonist approved by the United States Food and Drug Administration, a
buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder to prior authorization or step therapy. Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Digest Key
Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: YESBill Text
The people of the State of California do enact as follows:
SECTION 1.
Section 1342.75 is added to the Health and Safety Code, to read:1342.75.
Notwithstanding any other law, a health care service plan shall not subject(a) A naloxone product or another opioid antagonist approved by the United States Food and Drug Administration.
(b) A
buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder to prior authorization or step therapy. disorder.
SEC. 2.
Section 10123.1934 is added to the Insurance Code, to read:10123.1934.
Notwithstanding any other law, a health insurer shall not subject(a) A naloxone product or another opioid antagonist approved by the United States Food and Drug Administration.
(b) A
buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder to prior authorization or step therapy. disorder.